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Objectives. The goal of this study was to determine the feasi- 
bility, safety, sensitivity and specificity of transesophageal dobut- 
amine stress echocardiography for the detection of coronary 
artery disease. 
Background. Dobutamine stress echocardiography as been 
shown to be an extremely sensitive and specific noninvasive 
technique for the detection of myocardial ischemia. However, 
inadequate ransthoracic images preclude the use of dobutamine 
stress echocardiography in a small but significant group of 
patients. Transesophageal chocardiography provides better es- 
olution than that obtained with routine transthoracic imaging. 
Methods. Patients scheduled for routine cardiac catheteriza- 
tion underwent transesophageal dobutamine stress echocardiog- 
raphy. All patients underwent coronary arteriography within 48 h 
of the study, and lesion severity was determined by quantitative 
coronary angiography. Significant coronary obstruction was de- 
fined as stenosis >50%. 
Results. Fifty-one male patients were enrolled in the study; six 
were excluded for technical reasons. There were no adverse 
outcomes or complications. Of 27 patients with significant coro- 
nary artery disease, 22 had positive study results (sensitivity 82%). 
Of 13 patients without significant obstructive coronary disease, 1
had a false positive study result (specificity 93%). In patients with 
a minimal umen diameter <1.25 mm, sensitivity was >80%, and 
in patients with a minimal umen diameter >1.5 mm, sensitivity 
was < 70%, suggesting that lesions with a minimal lumen diameter 
< 1.25 mm are more likely to be physiologically significant. 
Conclusions. Transesophageal dobutamine stress eehocardiog- 
raphy is a feasible, safe and accurate technique for the detection 
of myocardial ischemia. There are inherent limitations to this 
technique in that transesophageal echocardiography must be 
performed. Transesophageal dobutamine stress echocardiogra- 
phy may allow extension of dobutamine stress testing to patients 
with inadequate transthoracic echocardiographic imaging and 
may provide an opportunity for further esearch applications. 
(J Am Coll Cardiol 1995;25:823-9) 
Dobutamine stress testing in combination with two-dimensional 
transthoracic echocardiographic imaging provides accurate 
diagnostic and prognostic information in patients at risk for 
coronary artery disease (1-5). In patients with significant 
coronary artery disease, graded infusion of dobutamine r sults 
in the controlled evelopment of myocardial ischemia. The 
echocardiographic equivalent of myocardial ischemia is a new 
or worsening wall motion abnormality (6-8). The sensitivity 
and specificity of transthoracic dobutamine stress testing 
equals other forms of noninvasive valuation of coronary 
artery disease (9-11). Dobutamine stress echocardiography 
has been shown to be accurate in risk stratification after myocar- 
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dial infarction (12-14), preoperative risk assessment (15-17) and 
identification of viable and hibernating myocardium (18-20). 
In a small but significant number of patients, transthoracic 
echocardiographic images are not of sufficient quality to allow 
accurate delineation of endocardial boundaries. This is most 
commonly seen in obese patients or in patients with obstructive 
pulmonary disease or chest wall deformities. In these patients, 
dobutamine stress testing using transthoracic imaging is inad- 
equate. Transesophageal echocardiography can overcome 
some of the limitations inherent in transthoracic echocar- 
diography (21,22). Improved visualization of epicardial and 
endocardial borders is one of the major advantages of trans- 
esophageal echocardiography. As a result, transesophageal 
echocardiography is used to monitor patients at high risk for 
intraoperative ischemia (6-8,23,24). 
This study attempted to evaluate the potential role of 
transesophageal chocardiography during graded obutamine 
infusion in screening patients for obstructive coronary artery 
disease. We performed a prospective study to determine the 
safety, feasibility, sensitivity and specificity of transesophageal 
dobutamine stress echocardiography for the detection of cor- 
onary artery disease. 
01995 by the American College of Cardiology 0735-1097/95/$9.50 
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Methods  
Study patients. Subjects were recruited from patients un- 
dergoing elective cardiac catheterization for evaluation of 
chest pain at the Atlanta Veterans Affairs Medical Center. 
Exclusion criteria included 1) history of myocardial infarction 
within 1 month; 2) history of ventricular tachycardia or ven- 
tricular fibrillation; 3) current atrial fibrillation, atrial flutter or 
multifocal atrial tachycardia; 4) clinical evidence of significant 
valvular heart disease by echocardiography; 5) unstable angina; 
and 6) history or evidence of mediastinal, pulmonary or 
esophageal mass. All patients underwent cardiac catheteriza- 
tion within 48 h of the study. In all patients antianginal 
medications were continued uring the day of the study. All 
patients gave informed written consent for this study. The 
study protocol was approved by the Human Investigations 
Committee of Emory University School of Medicine. 
Study protocol. Transesophageal imaging was performed 
at baseline and during dobutamine infusion. All patients were 
studied in the left lateral decubitus position. Before passing the 
transesophageal probe, 1 to 3 mg of intravenous midazolam 
was administered for sedation, and 10% lidocaine spray was 
used for topical anesthetic. Heart rate, blood pressure and 
pulse oximetry were continuously monitored uring the pro- 
cedure. A 12-lead electrocardiogram (ECG) was obtained 
during each stage of the protocol. All echocardiographic 
studies were performed using a Hewlett-Packard Sonos 1500 
and a 5-MHz biplane transesophageal probe. At baseline, 
biplane images were obtained in the midesophageal nd 
transgastric views. During dobutamine infusion, the transesoph- 
ageal probe was left in the transgastric position to monitor for 
the development of regional wall motion abnormalities. After 
baseline images were obtained, dobutamine infusion was be- 
gun at 10 /xg/kg body weight per rain. The infusion was 
increased in increments of 10/zg/kg per min at 3-rain intervals 
up to a maximal infusion rate of 40/zg/kg per rain. If 85% of 
the predicted maximal heart rate was not attained at 40/xg/kg 
per rain, then 0.6 mg of atropine was given intravenously. 
Transgastric short- and long-axis images at each level of 
dobutamine infusion were obtained 2 rain into each stage. A 
12-lead ECG was also obtained 2 min into each stage. Criteria 
for termination of infusion were attainment of 85% of the 
predicted maximal heart rate, development of new or wors- 
ened wall motion abnormality, angina, arrhythmia, ECG 
changes consistent with ischemia or intolerance of the trans- 
esophageal probe. 
At peak dose, images were obtained in the transgastric 
view, and the probe was then withdrawn into the esophagus for 
the lower esophageal views. Baseline and peak images were 
digitized in a quad screen continuous loop format for later 
review and analysis. 
Analysis of eehoeardiograms. All echocardiographic stud- 
ies were interpreted in blinded manner by two experienced 
echocardiographers (S.F., W.R.T.) using a modified version of 
a 16-segment model previously described (25). The develop- 
ment of a new or worsened regional wall motion abnormality 
was considered to be a positive echocardiographic result. Any 
conflicts between the two reviewers' interpretations were set- 
tled by discussion. 
Quantitative coronary angiography. Coronary angiogra- 
phy was performed in all patients utilizing the Judkins or 
multipurpose t chnique with either 6F or 7F catheters. Quan- 
titative coronary angiography was performed as previously 
described (26). Significant coronary artery disease was defined 
as >50% stenosis of a major epicardial coronary artery or a 
major branch vessel. In patients who had coronary artery 
bypass grafts, percent stenosis of saphenous vein or internal 
mammary grafts was determined in the same manner. 
Results  
Study group. Transesophageal dobutamine stress echocar- 
diography was attempted in 51 male patients. Two patients 
(4%) did not tolerate intubation with the transesophageal 
probe sufficiently to allow continuous imaging; therefore, the 
remaining 49 patients comprised the study group (61.6 _+ 1.2% 
[mean + SEM]). Twenty-four patients (49%) had one-vessel 
disease; 10 (20%) had two-vessel disease; none had three- 
vessel or left main coronary artery disease; and 15 (31%) had 
nonobstructive coronary disease. Of the 15 patients who had 
nonobstructive coronary disease, 7 had completely normal 
coronary anatomy by angiography, and 8 had mild lumen 
irregularities. Of the entire study group, 20 patients (41%) had 
a previous history of myocardial infarction and 19 (39%) had 
undergone revascularization. 
All patients were being evaluated for a chest pain syndrome 
and had either chronic stable angina (40%) or atypical chest 
pain symptoms (60%). All patients tudied had at least one 
significant risk factor for coronary artherosclerotic heart dis- 
ease. Using family history, male gender, age >55 years, hyper- 
tension, diabetes mellitus, hypercholesterolemia and history of 
tobacco use as the major risk factors, 32 patients (65%) had one 
to three cardiac risk factors, and 17 (35%) had more than three 
cardiac risk factors. 
Feasibility. In four studies (8%) the results were consid- 
ered inadequate for interpretation because of poor image 
quality either at baseline or during stress imaging. In two 
patients (4%) the test was terminated before dobutamine 
infusion because the baseline images were inadequate for 
interpretation (one patient had a large ventral hernia, the 
other a documented history of hiatal hernia). In two other 
patients (4%), baseline images were adequate for interpreta- 
tion, but images acquired uring dobutamine infusion became 
unacceptable, and these studies were considered incomplete 
(one patient had a documented history of hiatal hernia, the 
other a long history of gastroesophageal ref ux). 
Transesophageal dobutamine stress echocardiography was 
successful in 45 patients (92%). A total of five patients (10%) 
were excluded from the final analysis because they did not 
attain the target heart rate. In five patients, 0.6 mg of atropine 
was given to increase the chronotropic response to reach 
maximal heart rate. Of these patients, three did not attain the 
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target heart rate and were excluded from the final analysis. 
Two other patients did not attain the target heart rate but were 
not given atropine at the discretion of the operator and were 
also excluded. Mean study duration from the time of trans- 
esophageal intubation to completion of peak stress imaging 
was 15.6 _+ 0.7 rain. For studies with positive results, mean 
study duration was 14.6 _+ 0.9; for studies with negative results, 
mean study duration was 16.3 _+ 1.0 (p < 0.05). 
Safety. No patient experienced a complication or adverse 
outcome because of esophageal intubation. All ECGs imme- 
diately after intubation and before dobutamine infusion had no 
evidence of ischemia. One patient (2 _+ 0.038%) had a brief 
period of asymptomatic supraventricular tachycardia atpeak 
dobutamine infusion that responded to cessation of the infu- 
sion and a small dose of intravenous beta-adrenergic blocking 
agent. 
Transesophageal dobutamine stress echocardiography. A
total of 40 patients (82%) who had adequate images for 
analysis were included in the final analysis. Mean maximal 
heart rate was 110 _+ 4.8 beats/min in patients with positive 
transesophageal dobutamine stress echocardiograpbic results 
and 132 _+ 1.9 beats/rain in those with negative results (p < 
0.05). Mean peak dobutamine dose was 28.3 - 1.6/~g/kg per 
rain for positive and 31.8 + 2.1 ~g/kg per rain for negative 
echocardiographic results (p = 0.06). Representative digitized 
images from studies with normal and abnormal findings are 
shown in Figure i. 
Twenty-two f 27 patients with significant coronary artery 
disease had positive dobutamine chocardiographic results 
(sensitivity 82%). One of the 13 patients without significant 
obstructive coronary disease had false positive findings on the 
dobutamine stress echocardiogram (specificity 93%). Sensitiv- 
ity of transesophageal dobutamine stress echocardiography for 
patients with single-vessel versus multivessel disease is shown 
in Figure 2. For patients with disease in one major coronary 
artery, sensitivity was 76% (13 of 17) and 90% (9 of 10) for 
those with two-vessel disease. 
We also investigated the relation between lesion severity 
and a positive echocardiographic result. As lesion severity 
increased, the sensitivity of transesophageal dobutamine stress 
echocardiography improved (Fig. 3). Sensitivity was 82% for 
lesions with stenosis >50% and 100% for those with stenosis 
>80% (p < 0.005). 
The effect of minimal lumen diameter on sensitivity is 
depicted in Figure 4. Sensitivity was >80% for lesions with a 
minimal umen diameter <1.25 mm and decreased to <70% 
for those with a minimal lumen diameter >1.5 mm (p < 0.0l 0). 
Fifteen of 18 patients with a minimal umen diameter -<1 mm 
had positive findings on the transesophageal dobutamine stress 
echocardiogram (sensitivity 83%). Two of the three patients 
with a minimal umen diameter <1 mm and negative findings 
on the transesophageal dobutamine stress echocardiogram had 
lesions in the midportion of the diseased vessels (one circum- 
flex and one left anterior descending coronary artery); the 
third patient had a right coronary artery lesion that supplied an 
area with a baseline wall motion abnormality from a previous 
inferior infarction. 
Neither the development of symptoms nor ECG findings 
during the graded dobutamine infusion were found to be 
sensitive predictors of significant coronary artery disease. Only 
three patients in the study group had positive stress ECG 
results during dobutamine infusion, and two of these experi- 
enced their typical chest pain during dobutamine infusion. All 
three patients had significant obstructive coronary disease of at 
least one major coronary artery (specificity 100%), and all 
three had positive findings on the transesophageal dobutamine 
stress echocardiogram. However, of the 27 patients with sig- 
nificant obstructive coronary artery disease, these were the 
only positive ECG findings (sensitivity 11%). There were no 
false positive stress ECG results. 
Discuss ion  
Dobutamine stress echocardiography is rapidly becoming 
the pharmacologic stress imaging technique of choice in many 
cardiovascular centers. One factor limiting the use of trans- 
thoracic dobutamine stress echocardiography in a small but 
significant number of patients i  the ability to obtain adequate 
images. This is most common in obese patients or those with 
chronic obstructive pulmonary disease or chest wall deformi- 
ties. Transesophageal chocardiography has been shown to 
avoid some of the pitfalls inherent in obtaining images by the 
transthoracic approach (20,21) and is a sensitive method for 
the detection of ischemia-indueed segmental wall motion 
abnormalities (7,23,24). 
The important new findings in our study are that trans- 
esophageal dobutamine stress echocardiography 1) is safe and 
feasible, 2) is sensitive and specific for noninvasive valuation 
of coronary artery disease, and 3) has some potentially signif- 
icant limitations. 
Feasibility and safety. No significant adverse reactions 
were observed in our study group. The procedure was gener- 
ally well tolerated by patients, with only 4% of the studies 
terminated because of patient discomfort. Total time of trans- 
esophageal probe insertion was relatively short (15.6 + 
0.7 rain). One patient developed an asymptomatic supraven- 
tricular tachycardia that resolved on termination ofthe dobut- 
amine infusion and subsequent administration f a small dose 
of intravenous beta-blocker. There were no complications 
associated with insertion of the transesophageal probe. 
In a small number of patients (8%), poor echocardio- 
graphic images resulted in either termination of the study or 
the inability to detect regional wall motion abnormalities. This 
appeared to be related to the presence of a hiatal hernia or 
related gastroesophageal disease in these patients. Bowles et 
al. (27) recently reported an association between the presence 
of hiatal hernias and the inability to obtain adequate trans- 
esophageal images. This is presumably due to an abnormal 
anatomic relationship between the heart and the esophagus. 
Sensitivity and specificity. Overall sensitivity for lesion 
stenosis >50% was 82%, and overall specificity was 93%. In 
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Figure 1. Representative images 
from studies with normal and ab- 
normal findings. A, Example of 
normal findings in digitized trans- 
gastric horizontal images during di- 
astole and systole both at rest and 
during peak dobutamine infusion. 
There is no evidence of regional 
wall motion abnormalities. B, Ex- 
ample of abnormal results. Left, 
diastolic images; bottom right, 
peak dobutamine image during sys- 
tole; white arrows indicate an area 
of dobutamine-induced hypokine- 




patients with single-vessel disease, sensitivity was 76%, and 
specificity was 91%. In patients with double-vessel disease, 
sensitivity was 90%, and specificity was 91%. Sensitivity of 
transesophageal dobutamine stress echocardiography appears 
to be similar to that of transthoracic dobutamine stress echo- 
cardiography. Sawada et al. (2) performed transthoracic do- 
Systole 
butamine stress echocardiography in 35 patients with signifi- 
cant obstructive coronary artery disease, defined as a lesion 
stenosis of at least 50%. Sensitivity and specificity were 89% 
(31 of 35) and 85% (17 of 20), respectively. Mazeika et al. (3) 
studied 36 patients by transthoracic e hocardiography who had 
at least one major epicardial coronary artery with a stenosis of 
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Figure 2. Sensitivity oftransesophageal dobutamine stress echocardi- 
ography for one- versus two-vessel disease. *p < 0.010. 
at least 70%, and obtained an overall sensitivity and specificity 
for detection of significant coronary artery disease of 78% and 
93%, respectively. Of 70 patients tudied by transthoracic 
dobutamine stress echocardiography by Cohen et al. (4), 44 of 
51 with significant obstructive coronary artery disease had 
positive findings (sensitivity 86%), and 18 of 19 without 
significant obstructive coronary artery disease had negative 
findings (specificity 93%). Overall sensitivity of 82% and 
specificity of 93% in the present study compares favorably with 
the results of previous transthoracic studies; however, we did 
not directly compare transthoracic and transesophageal stress 
images. In the patients at our institution, up to 30% have 
inadequate ransthoracic e hocardiographic endocardial defi- 
nition. 
Of the five patients with obstructive coronary artery disease 
and negative transesophageal dobutamine stress echocardio- 
graphic results, four had single-vessel disease. Two of these 
patients had diffuse disease involving marginal branches of the 
circumflex artery, and the lesions were in the midportion of 
these vessels. The other two patients had lesions involving the 
midportion of the right coronary artery that supplied previ- 
ously damaged regions and had baseline wall motion abnor- 
malities. The remaining patient had two-vessel disease with a 
lesion in the midportion of the left anterior descending coro- 
nary artery that supplied the apex and a lesion in the midpor- 
tion of a marginal branch of the circumflex artery. Therefore, 
ischemic regions may not have been visualized throughout the 
Figure 3. Effect of lesion severity on calculated sensitivity. As lesion 
severity increased, sensitivity of transesophageal dobutamine stress 
echocardiography to detect significant lesions increased. *p < 0.005 
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Figure 4. Effect of minimal lumen diameter (mm) on sensitivity. For 
lesions with minimal lumen diameter < 1.25 mm, sensitivity was >80% 
compared with lesions with minimal lumen diameter >1.5 mm, for 
which sensitivity, decreased <70%. *p < 0.010 compared with minimal 
lumen diameter <0.75 mm by chi-square analysis. 
entire study, but there was no predilection for a particular 
vascular bed. 
Overall specificity of transesophageal dobutamine stress 
echocardiography was 93%. One of 14 patients with nonob- 
structive coronary artery disease had false positive study 
results. This patient had left ventricular hypertrophy and 
normal coronary anatomy by angiography. At peak dose, the 
patient developed anteroseptal hypokinesia without ECG evi- 
dence of ischemia. The patient had no chest pain or dyspnea, 
and the test was terminated and the results labeled positive. 
Subsequent cardiac catheterization revealed no evidence of 
obstructive coronary disease. Patients with hypertension and 
myocardial hypertrophy may have signs and symptoms of 
myocardial ischemia in the absence of obstructive disease of 
the epicardial coronary arteries. Previous investigators (28) 
have suggested that this may be related to either microvascular 
disease or impaired vasodilatory reserve. 
Positive ischemic ECG changes during dobutamine infusion 
were seen in only three patients, all of whom had significant 
coronary artery disease and positive chocardiographic results. 
These findings compare favorably with published reports using 
transthoracic imaging (9,29). 
To our knowledge only one other investigator has utilized 
transesophageal imaging during dobutamine infusion. In a 
preliminary report, Panza et al. (30) used transesophageal 
stress dobutamine echocardiography for detection of coronary 
artery disease. Using 70% obstruction as the definition of 
significant obstructive disease, their series had a sensitivity and 
specificity of 88% and 100%, respectively. 
Previous tudies utilizing other forms of stress transesoph- 
ageal imaging have demonstrated similar results. Agati et al. 
(31) combined transesophageal imaging with dipyridamole 
infusion in 32 patients and obtained an overall sensitivity and 
specificity for identifying significant obstructive coronary artery 
disease, defined as lesion stenosis >70%, of 92% and 100%, 
respectively. Sensitivity of transesophageal dipyridamole stress 
echocardiography for single-, double- and triple-vessel disease 
was 67%, 100% and 100%, respectively. High quality images 
for analysis were obtained in all patients. Lambertz et al. (32) 
performed transesophageal imaging with simultaneous atrial 
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pacing in 50 patients, all of whom had adequate images. 
Significant coronary artery disease was defined as >50% 
lumen diameter narrowing of a major coronary vessel, and 
their procedure had an overall sensitivity and specificity of 
93% and 100%, respectively. For single-, double- and triple- 
vessel disease, the sensitivity of their test was 85%, 100% and 
100%, respectively. When the results of these studies were 
compared with those in our study group, the overall sensitivity 
and specificity were favorable. The overall success rate for 
obtaining adequate images in our group was 88%, which was 
lower than that reported in previous tudies. 
Analysis of lesion severity using minimal lesion diameter. 
Minimal lumen area or diameter obtained by quantitative 
angiography may be a more physiologic marker for severity of 
coronary artery lesions than percent diameter stenosis deter- 
mined by visual estimation (33-35). In the present study, 
analysis of patients with a minimal umen diameter <1.25 mm 
yielded an overall sensitivity >80% but <70% for patients with 
a minimal umen diameter >1.5 mm. Segar et al. (36) showed 
that detection of stenosis in individual coronary arteries is 
improved in those lesions with a minimal lumen diameter 
<1 mm (sensitivity 86%), indicating that these lesions are 
more likely to be physiologically significant. Recently, Baptista 
et al. (37) reported that in patients with a minimal lumen 
diameter -<1.07 ram, sensitiviW of dobutamine stress echocar- 
diography in predicting the physiologic significance of a coro- 
nary stenosis was 94%. Therefore, lesions with a minimal 
lumen diameter <1 mm are likely to be correctly identified 
using either the transthoracic or transesophageal approach. 
Potential imitations of transesophageal dobutamine stress 
echocardiography. The inherent limitation of this study is the 
necessity of obtaining a transesophageal chocardiogram. The 
contraindications of transesophageal echocardiography limit 
patient selection. Ischemia that is confined to the apex of the 
left ventricle may be missed by monitoring for segmental wall 
motion abnormalities from a single transgastric short-axis 
position (38). Shah et al. (38) studied 94 patients in the 
intensive care unit or intraoperatively for development of 
segmental wall motion abnormalities and found that 7 of 20 
segmental wall motion abnormalities were visualized only in 
the longitudinal plane. Therefore, at each stage of dobutamine 
infusion we utilized the longitudinal long-axis view to increase 
detection of segmental wall motion abnormalities. However, 
utilizing the transgastric view of the left ventricle at midcavity 
continuously during dobutamine infusion does not provide a 
view of all ventricular segments, and significant lesions located 
in the mid or distal portion of vessels may not be detected 
using this approach. 
At our institution there is a high prevalence of coronary 
artery disease, and in such patients there is a high pretest 
probability of a positive result. In our study group there was a 
high incidence of previous myocardial infarction and revascu- 
larization. All patients with significant coronary artery disease 
had one- or two-vessel disease, and no patient had three-vessel 
or left main coronary disease. Similarly, only 7 of the 15 
patients who comprised the group described as having nonob- 
structive coronary disease had angiographically normal coro- 
nary anatomy. This highly selected group of patients with a 
high prevalence of coronary artery disease may tend to alter 
the predictive accuracy of a noninvasive screening test such as 
transesophageal dobutamine stress echocardiography, 
Five of our patients did not achieve maximal heart rate 
during dobutamine infusion, and these studies were considered 
incomplete. In our protocol, medications were not discontin- 
ued 24 h before the study. This may have contributed to the 
failure to obtain adequate heart rate responses in all of our 
patients. 
Conclusions. Transesophageal dobutamine stress echocar- 
diography as a screening test for detection of coronary artery 
disease in the general population may be of limited clinical 
utility. Continuing improvement i  echocardiographic imaging 
systems and the development of intravenous contrast agents 
that improve ndocardial border definition may further educe 
the need for transesophageal imaging during stress studies. 
However, we showed that his test is safe, feasible and sensitive 
for the detection of significant coronary artery disease and may 
be useful in a select group of patients. This test may be useful 
for research purposes only or may become clinically useful 
when smaller transesophageal probes are developed to allow 
better patient acceptance. 
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